Research location
Salt
Girona, Spain
Advertisement
Research activity in Salt
Girona, SpainCureCurrent currently publishes aggregate city-level research activity for this location: 16 trials and 16 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Salt
16 linked trials · page 1 of 1A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)NCT07282574 · 2026-03-10 · 1 site observation
RECRUITING
Retrieval of Economic Incentives and Information on Quality-of-care Indicators in Primary CareNCT06829589 · 2025-02-03 · 1 site observation
ACTIVE_NOT_RECRUITING
A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical PracticeNCT06251986 · 2024-02-26 · 1 site observation
COMPLETED
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple SclerosisNCT05269004 · 2022-05-03 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)NCT05147220 · 2021-12-16 · 1 site observation
ACTIVE_NOT_RECRUITING
Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSNCT04788615 · 2021-07-23 · 1 site observation
COMPLETED
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSNCT03650114 · 2018-12-28 · 1 site observation
ACTIVE_NOT_RECRUITING
Efficacy and Safety of BIIB033 (Opicinumab) as an Add-on Therapy to Disease-Modifying Therapies (DMTs) in Relapsing Multiple Sclerosis (MS)NCT03222973 · 2017-11-15 · 1 site observation
TERMINATED
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)NCT03114657 · 2017-03-29 · 1 site observation
TERMINATED
Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)NCT02936037 · 2016-12-01 · 1 site observation
TERMINATED
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)NCT02861014 · 2016-09-09 · 1 site observation
COMPLETED
Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Tiotropium BromideNCT01543919 · 2012-04-01 · 1 site observation
COMPLETED
A Study of Ocrelizumab in Participants With Primary Progressive Multiple SclerosisNCT01194570 · 2011-03-02 · 1 site observation
COMPLETED
A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients.NCT00808288 · 2010-03-01 · 1 site observation
COMPLETED
A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's DiseaseNCT00912288 · 2009-09-01 · 1 site observation
TERMINATED
A Study of RO5313534 as Add-on to Donepezil Treatment in Patients With Mild to Moderate Alzheimer's DiseaseNCT00884507 · 2009-05-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.